title: A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease.
authors.forename: P G
authors.initials: PG
authors.lastname: Maslak
authors.forename: T
authors.initials: T
authors.lastname: Dao
authors.forename: M
authors.initials: M
authors.lastname: Gomez
authors.forename: S
authors.initials: S
authors.lastname: Chanel
authors.forename: J
authors.initials: J
authors.lastname: Packin
authors.forename: T
authors.initials: T
authors.lastname: Korontsvit
authors.forename: V
authors.initials: V
authors.lastname: Zakhaleva
authors.forename: J
authors.initials: J
authors.lastname: Pinilla-Ibarz
authors.forename: E
authors.initials: E
authors.lastname: Berman
authors.forename: D A
authors.initials: DA
authors.lastname: Scheinberg
mesh_terms: D000328:Adult; D000368:Aged; D000595:Amino Acid Sequence; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000737:chemistry*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010865:Pilot Projects
chemical_list: D019496:Cancer Vaccines; D016044:Fusion Proteins, bcr-abl